Repare Therapeutics
Clinical trials sponsored by Repare Therapeutics, explained in plain language.
-
New drug combo for Hard-to-Treat cancers shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer pill tested in early trial – but study halted
Disease control TerminatedThis early-phase trial tested an oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study was terminated early, so full results may not be availa…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental cancer combo shows promise but trial halted early
Disease control TerminatedThis early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC